Table 1.
Clinical, functional and biochemical parameters of subjects
| COPD (n=66) | Control (n=59) | p | |
|---|---|---|---|
| Sex (M/F) | 61/5 | 50/9 | 0.174 |
| Age | 63.9 (10.7) | 61.0 (6.5) | 0.077 |
| Smoking status, n (%) | |||
| Smokers | 57 (86.4) | 2 (3.4) | 0.001 |
| Ex-smokers | 7 (10.6) | 7 (11.9) | |
| Non-smokers | 2 (3) | 50 (84.7) | |
| Comorbidity | |||
| Any | 41 (62.1) | 45 (76.3) | 0.352 |
| Hypertension, n (%) | 12 (18.2) | 8 (13.6) | |
| Diabetes mellitus, n(%) | 10 (15.2) | 5 (8.5) | |
| Ischemic heart disease,n(%) | 3 (4.5) | 1 (1.7) | |
| FEV1, % predicted | 46.9 (16.3) | 89.7 (5.5) | 0.001 |
| FVC, % predicted | 66.0 (17.8) | 93.2 (5.8) | 0.001 |
| FEV1/FVC, % | 55.5 (13.2) | 89.9 (5.2) | 0.001 |
| Gold group, n (%) | |||
| A | 20 (30.3) | ||
| B | 26 (39.4) | ||
| C | 6 (9.1) | ||
| D | 14 (21.2) | ||
| HDL-C (mg/dL) | 48.8 (5.9) | 54.9 (10.2) | 0.001 |
| LDL-C (mg/dL) | 113.1 (19.5) | 100.0 (26.7) | 0.003 |
| Total Cholesterol (mg/dL) | 207.2 (23.8) | 180.2 (34.3) | 0.001 |
| Triglyceride (mg/dl) | 155.6 (30.5) | 125.3 (43.7) | 0.001 |
| PON1 activity (U mL−1) | 199.1 (134.5) | 129.2 (112.5) | 0.002 |
| ARE activity (U mL−1) | 21.3 (14.9) | 33.5 (39.5) | 0.021 |
ARE: Arylesterase; FEV1: Forced exspiratory volume in 1 second; FVC: Forced vital capacity; COPD: chronic obstructive pulmonary disease